Table 4.

Differences in CD4, CD8 and CD4/CD8 levels in 30 PCa patients based on PSA levels and different Gleason score

Group (N)	CD4 (%)	CD8 (%)	CD4/CD8
A (10)	38.03 ± 4.10	27.75 ± 7.11	1.58 ± 0.45
B (10)	27.72 ± 2.53c	19.90 ± 5.95d	1.56 ± 0.73
C (10)	20.09 ± 1.60a,b	23.84 ± 7.83	0.97 ± 0.35e,f
D (8)	38.74 ± 4.60	27.47 ± 5.51	1.50 ± 0.24
E (9)	30.42 ± 2.44i	20.68 ± 6.45	1.58 ± 0.52
F (13)	21.12 ± 2.57g,h	22.46 ± 8.84	1.16 ± 0.72

Notes: Group A, PSA < 10 ng/mL; group B, PSA 10–20 ng/mL; group C, PSA > 20 ng/mL; group D, Gleason grade < 7; group E, Gleason grade 7; group F, Gleason grade > 7.

^aP = 0.000 vs group A;

^bP = 0.000 vs group B;

^cP = 0.000 vs group A;

^dP = 0.025 vs group A;

^eP = 0.016 vs group A;

^fP = 0.019 vs group B;

^gP = 0.000 vs group D;

^hP = 0.000 vs group E;

ⁱP = 0.000 vs group D. N is the numbers of the cases. Data are presented as mean ± standard deviation.

Abbreviations: PCa, prostate cancer; PSA, prostate-specific antigen.